KDR and colorectal cancer: In mouse tumor models, VEGF-A/VEGFR-2 and PD-1 blockade induces strong and synergic antitumor responses and limits T-cell exhaustion in VEGF-A-expressing tumor compared to monotherapies in mouse models of MSS colorectal cancer (44, 50).